Price Alert: Shares of Medicenna (MDNA) Trade 10.53% Higher at Midday August 5

Equities Staff  |

Medicenna Therapeutics Corp (NASDAQ: MDNA) has risen $0.16 (10.53%) and sits at $1.68, as of 11:57:05 est on August 5.

61,400 shares have traded hands.

The Company rose 3.97% over the last 5 days and shares advanced 36.52% over the last 30 days.

Medicenna expects its next earnings on 2022-08-12.

For technical charts, analysis, and more on Medicenna visit the company profile.

About Medicenna Therapeutics Corp

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna's long-acting IL2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna's lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

To get more information on Medicenna Therapeutics Corp and to follow the company's latest updates, you can visit the company's profile page here: Medicenna Therapeutics Corp's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content